Recent Advances in Frontotemporal Dementia

ABSTRACT: Frontotemporal dementia (FTD) is a devastating neurodegenerative condition for which there is currently no effective treatment. Although it is much less common than Alzheimer’s disease, the impact of FTD is increased by its relatively early onset and high heritability. Clinical heterogeneity and overlap with other neurodegenerative and psychiatric syndromes complicate diagnosis. However, recent advances in our understanding of the molecular basis of FTD provide a foundation for the development of much-needed biomarkers and targeted therapies. This review provides a summary of the recently revised clinical criteria for FTD, highlights diagnostic challenges, briefly summarizes recent molecular discoveries and then focuses on promising developments in biomarkers and clinical trials.

• Publication year

  2022

• Venue

  Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

• Publication date

  2022-05-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1017/cjn.2022.69PMID 35634749
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overview of tau PET molecular imaging

  2022cited by this paper
• A multicentre validation study of the diagnostic value of plasma neurofilament light

  2021cited by this paper
• Structure-based classification of tauopathies

  2021cited by this paper
• FDG-PET in presymptomatic C9orf72 mutation carriers

  2021cited by this paper
• FTLD Treatment: Current Practice and Future Possibilities.

  2021cited by this paper
• Expanding the Spectrum of Movement Disorders Associated With C9orf72 Hexanucleotide Expansions

  2021cited by this paper
• TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients

  2020cited by this paper
• Transcranial stimulation in frontotemporal dementia: A randomized, double‐blind, sham‐controlled trial

  2020cited by this paper
• A clinical-radiological framework of the right temporal variant of frontotemporal dementia

  2020cited by this paper
• Adeno‐associated virus serotype 1‐based gene therapy for FTD caused by GRN mutations

  2020cited by this paper
• Detection

  2020cited by this paper
• Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders.

  2020cited by this paper
• Tau PET imaging in neurodegenerative tauopathies—still a challenge

  2019cited by this paper
• Language impairment in progressive supranuclear palsy and corticobasal syndrome

  2019cited by this paper
• 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration

  2019cited by this paper
• Genetic predictors of survival in behavioral variant frontotemporal degeneration

  2019cited by this paper
• Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis.

  2019cited by this paper
• Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest

  2019cited by this paper
• Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia.

  2019cited by this paper
• A walk through tau therapeutic strategies

  2019cited by this paper
• 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes

  2019cited by this paper
• P3‐472: UNVEILING THE COGNITIVE UNDERPINNINGS OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING ACROSS AGE

  2018cited by this paper
• Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study

  2018cited by this paper
• Towards a TDP-43-Based Biomarker for ALS and FTLD

  2018cited by this paper
• Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

  2018cited by this paper
• Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria

  2017cited by this paper
• Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis

  2017cited by this paper
• Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration

  2017cited by this paper
• The social and economic burden of frontotemporal degeneration

  2017cited by this paper
• Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid

  2017cited by this paper
• Poly(Gp) Proteins Are A Useful Pharmacodynamic Marker For C9Orf72-Associated Amyotrophic Lateral Sclerosis

  2017cited by this paper
• Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria

  2017cited by this paper
• Episodic Memory Dysfunction in Behavioral Variant Frontotemporal Dementia: A Clinical And FDG-PET Study

  2017cited by this paper
• Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes

  2016cited by this paper
• The clinical spectrum of sporadic and familial forms of frontotemporal dementia

  2016cited by this paper
• Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes

  2016cited by this paper
• Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors

  2016cited by this paper
• Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs.

  2016cited by this paper
• Based on the Network Degeneration Hypothesis: Separating Individual Patients with Different Neurodegenerative Syndromes in a Preliminary Hybrid PET/MR Study

  2016cited by this paper
• MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases

  2016cited by this paper
• Genetics of FTLD: overview and what else we can expect from genetic studies

  2016cited by this paper
• Prion‐like propagation as a pathogenic principle in frontotemporal dementia

  2016cited by this paper
• Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies

  2016cited by this paper
• Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

  2016cited by this paper
• Neuropathology of frontotemporal dementia and related disorders

  2016cited by this paper
• Therapy and clinical trials in frontotemporal dementia: past, present, and future

  2016cited by this paper
• Advances in neuroimaging in frontotemporal dementia

  2016cited by this paper
• Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis.

  2015cited by this paper
• Oxytocin for frontotemporal dementia

  2015cited by this paper
• Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia

  2015cited by this paper
• Mutation analysis of C9orf72 in patients with corticobasal syndrome.

  2015cited by this paper
• Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia

  2015cited by this paper
• Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia

  2015cited by this paper
• Differential Cognitive and Affective Theory of Mind Abilities at Mild and Moderate Stages of Behavioral Variant Frontotemporal Dementia

  2015cited by this paper
• Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort

  2015cited by this paper
• New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications

  2014cited by this paper
• Cognition in corticobasal syndrome and progressive supranuclear palsy: A review

  2014cited by this paper
• Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS.

  2013cited by this paper
• Criteria for the diagnosis of corticobasal degeneration

  2013cited by this paper
• Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP

  2013cited by this paper
• Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia

  2013cited by this paper
• Targeted manipulation of the sortilin–progranulin axis rescues progranulin haploinsufficiency

  2013cited by this paper
• The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS

  2013cited by this paper
• Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia

  2013cited by this paper
• Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics

  2012cited by this paper
• Gray Matter Atrophy in Behavioral Variant Frontotemporal Dementia: A Meta-Analysis of Voxel-Based Morphometry Studies

  2012cited by this paper
• Episodic memory in frontotemporal dementia: a critical review.

  2012cited by this paper
• Primary progressive aphasia

  2012cited by this paper
• Alzheimer's pathology in primary progressive aphasia

  2012cited by this paper
• Extrapyramidal Syndromes in Frontotemporal Degeneration

  2011cited by this paper
• Classification of primary progressive aphasia and its variants

  2011cited by this paper
• Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD

  2011cited by this paper
• Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

  2011cited by this paper
• Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

  2011cited by this paper
• A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

  2011cited by this paper
• Suberoylanilide Hydroxamic Acid (Vorinostat) Up-regulates Progranulin Transcription

  2011cited by this paper
• Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias

  2011cited by this paper
• A highly sensitive assay for prion detection

  2011cited by this paper
• FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.

  2011cited by this paper
• Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Progression of language decline and cortical atrophy in subtypes of primary progressive aphasia

  2011cited by this paper
• The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease.

  2011cited by this paper
• Faculty Opinions recommendation of Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia.

  2011cited by this paper
• Real-time quaking-induced conversion

  2011cited by this paper
• Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

  2011cited by this paper
• Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study.

  2009cited by this paper
• Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members

  2009cited by this paper
• Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update

  2009cited by this paper
• Quantitative template for subtyping primary progressive aphasia.

  2009cited by this paper
• A new subtype of frontotemporal lobar degeneration with FUS pathology.

  2009cited by this paper
• Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration

  2009cited by this paper
• The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia

  2008cited by this paper
• Extrapyramidal symptoms in Frontotemporal Dementia: prevalence and clinical correlations.

  2007cited by this paper
• Epidemiology of frontotemporal dementia

  2007cited by this paper
• FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

  2007cited by this paper
• Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21

  2006cited by this paper
• Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.

  2006cited by this paper
• Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis

  2006cited by this paper
• Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17

  2006cited by this paper
• Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome.

  2006cited by this paper

• Predominant right temporal and frontal brain atrophy and progressive behavioral dementia. A case of prion gene mutation (PRNP)

  2025cites this paper
• Longitudinal behavioral and neuropsychiatric changes and their MRI correlates in predementia C9orf72 and GRN mutation carriers

  2025cites this paper
• Frontotemporal dementia as a consequence of GRN mutations: from disease cause to models to therapies.

  2025cites this paper
• Intrathalamic delivery of adeno-associated viral vector expressing progranulin as gene therapy for GRN-related frontotemporal dementia

  2025cites this paper
• Frontotemporal Dementia

  2024cites this paper
• THE GLYMPHATIC SYSTEM AND AMYOTROPHIC LATERAL SCLEROSIS.

  2024cites this paper
• Heterozygous p62/SQSTM1 mutation and right temporal variant of frontotemporal dementia: Α case report

  2024cites this paper
• Risk and progression of frontotemporal dementia in carriers of the TMEM106B protective genotype and its relationship with TDP-43 pathology

  2024cites this paper
• Amyloid-Induced Neurodegeneration: A Comprehensive Review through Aggregomics Perception of Proteins in Health and Pathology.

  2024cites this paper
• Neuropsychology and Quantitative Electroencephalography in a Case of Frontotemporal Dementia and Small Vessel Disease

  2024cites this paper
• miR-92a-3p and miR-320a are Upregulated in Plasma Neuron-Derived Extracellular Vesicles of Patients with Frontotemporal Dementia

  2024cites this paper